|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000019090 |
|
Date of registration:
|
01/11/2015 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water
|
|
Scientific title:
|
Reduced form of CoenzymeQ10 for Parkinson's disease - open trial of dose finding test and combination with hydrogen water - Dose finding test of reduced form of Coenzyme Q10 for Parkinson's disease |
|
Date of first enrolment:
|
2015/11/04 |
|
Target sample size:
|
45 |
|
Recruitment status: |
Complete: follow-up complete |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022073 |
|
Study type:
|
Interventional |
|
Study design:
|
Parallel Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Asako Yoritaka |
|
Address:
|
Fukuroyama 560, Koshigaya-shi, Saitama Japan
Japan |
|
Telephone:
|
048-975-0321 |
|
Email:
|
ayori@juntendo.ac.jp |
|
Affiliation:
|
Juntendo University Koshigaya Hospital Neurology |
|
|
Name:
|
Asako Yoritaka |
|
Address:
|
Fukuroyama 560, Koshigaya-shi, Saitama Japan
Japan |
|
Telephone:
|
048-975-0321 |
|
Email:
|
ayori@juntendo.ac.jp |
|
Affiliation:
|
Neurology Juntendo University Koshigaya Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: presence of parkinsonism unrelated to PD, dementia or other serious disease, malignant tumor, a history of brain surgery, and adverse events caused by medications. modified Hoehn and Yahr stage 4 and 5 without allergy for medication
Age minimum:
20years-old
Age maximum:
80years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Parkinson's disease
|
|
Intervention(s)
|
reduced form of CoQ10 300mg 16weeks
reduced form of CoQ10 600mg 16weeks
reduced form of CoQ10 600mg 16weeks hydrogen water 500ml(Suisosui 7.0) 16weeks
|
|
Primary Outcome(s)
|
|
The differences from baseline to 16th week of MDS-UPDRS part III and plasma % coenzyme Q10(CoQ10)
|
|
Secondary Outcome(s)
|
|
The differences of each parts or total of MDS-UPDRS The differences of urine 18OH-dG The differences of plasma reduced form of CoQ10
|
|
Source(s) of Monetary Support
|
|
Department of Neurology, Juntendo University Koshigaya Hospital
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|